Ionis Pharmaceuticals, Inc. IONS
44.50
0.69
1.57%
as of 25 Sep
- Market cap
- $7.4B
- P/E
- 0.0×
Follow IONS
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(40.04%) | (70.80%) | (67.62%) | (105.50%) | |
| (8.39%) | (11.69%) | (10.44%) | (18.90%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(14.89%) | (16.35%) | (13.84%) | (24.25%) | |
Average Days of Receivables |
9.29 | 25.55 | 25.42 | 24.57 | |
Free Cash Flow per Share |
(1.94) | (2.04) | (5.93) | (3.43) | |
Free Cash Flow |
(309.48) | (325.67) | (977.73) | (567.50) | |
Capital Expenditures |
(62.47) | (57.08) | (67.10) | (71.07) | |
Piotroski F-Score |
5.00 | 3.00 | 3.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(7.15%) | (5.43%) | (24.22%) | (12.91%) | |
Accounts Receivable Turnover |
45.47 | 11.93 | 18.66 | 15.69 | |
Accounts Payable Turnover |
1.01 | 0.45 | 0.80 | 0.45 | |
Inventory Turnover |
0.61 | 1.41 | 2.04 | 0.54 | |
Average Days of Payables |
443.85 | 644.29 | 545.12 | 1,087.09 | |
Days of Inventory on Hand |
324.38 | 230.53 | 116.38 | 1,158.40 | |
Tax Rate |
(0.01) | 0.00 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
91.16% | 97.02% | 87.42% | 105.79% | |
Selling, General and Administrative Expense of Revenue |
36.38% | 41.74% | 44.22% | 60.38% | |
Share Based Compensation of Revenue |
13.10% | 14.19% | 13.93% | 18.69% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.96 | 0.70 | 2.79 | 0.88 | |
Depreciation/Fixed assets |
0.00 | 0.05 | 0.07 | 0.09 | |
Capex/Depreciation |
223.91 | (9.73) | (7.03) | (4.93) | |
Revenue per Share |
6.05 | 5.90 | 6.42 | 5.28 | |
Operating CF per Share |
(1.55) | (1.68) | (5.52) | (3.00) | |
Capex per Share |
(0.39) | (0.36) | (0.41) | (0.43) | |
Capex to Sales |
0.06 | 0.06 | 0.06 | 0.08 | |
Net Profit Margin |
(26.51%) | (40.41%) | (30.90%) | (64.66%) |
Columns are period end dates